» Articles » PMID: 29290788

Investigating Esophageal Stent-Placement Outcomes in Patients with Inoperable Non-Cervical Esophageal Cancer

Overview
Journal J Cancer
Specialty Oncology
Date 2018 Jan 2
PMID 29290788
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Esophageal stent insertion in patients with inoperable esophageal cancer is usually accompanied with relatively high adverse symptoms and even mortality. The current study aims at investigating the outcomes of esophageal stenting in patients with inoperable non-cervical esophageal cancer. The current descriptive-analytical research evaluates 25 patients with esophageal cancer. The stent was placed in esophagus based upon endoscopy analysis with or without fluoroscopy and then the stent position and its opening was investigated by making use of CXRand Gastrografin studies. Demographic characteristics, dysphagia scores, stent placement side effects and the dysphagia-related indices were recorded and examined by taking advantage of a questionnaire which was administered pre and post stent insertion. The study population was comprised of 15 women and 10 men. The individuals' average age was 69.20 ± 11.25 years. Dysphagia mean score was lowered from a value of 4.32 ± 0.80 to 2.00 ± 1.22 (P-value<0.05). The prevalent side effects were chest pain (64%), dysphagia recurrence (40%), stent blockage (20%), stent migration (16%), GI bleeding (8%), and malposition (8%). Also, it was found out that 64% of the patients survived for 6 months. The results indicated that although esophageal stenting is accompanied with side effects in patients with inoperable esophageal cancer, but it is the most frequently used and the most reliable method in relieving dysphagia and improving dysphagia-related life indices.

Citing Articles

Low body mass index is associated with poor treatment outcome following radiotherapy in esophageal squamous cell carcinoma.

Lee J, Choi Y Radiat Oncol J. 2023; 41(1):40-47.

PMID: 37013417 PMC: 10073840. DOI: 10.3857/roj.2022.00640.


A literature review on the imaging methods for breast cancer.

Gerami R, Joni S, Akhondi N, Etemadi A, Fosouli M, Foroughi Eghbal A Int J Physiol Pathophysiol Pharmacol. 2022; 14(3):171-176.

PMID: 35891932 PMC: 9301184.


miR-33a-5p inhibits the progression of esophageal cancer through the DKK1-mediated Wnt/β-catenin pathway.

Song Q, Liu H, Li C, Liang H Aging (Albany NY). 2021; 13(16):20481-20494.

PMID: 34426559 PMC: 8436944. DOI: 10.18632/aging.203430.


Comparison of sublingual buprenorphine and intravenous morphine in reducing bone metastases associated pain in cancer patients.

Jamalian S, Sotodeh M, Mohaghegh F Eur J Transl Myol. 2019; 29(2):8098.

PMID: 31354919 PMC: 6615365. DOI: 10.4081/ejtm.2019.8098.


Application of Imaging Technologies in Breast Cancer Detection: A Review Article.

Lima Z, Ebadi M, Amjad G, Younesi L Open Access Maced J Med Sci. 2019; 7(5):838-848.

PMID: 30962849 PMC: 6447343. DOI: 10.3889/oamjms.2019.171.


References
1.
Baron T . Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med. 2001; 344(22):1681-7. DOI: 10.1056/NEJM200105313442206. View

2.
Aledavood A, Anvari K, Sabouri G . Esophageal Cancer in Northeast of Iran. Iran J Cancer Prev. 2015; 4(3):125-9. PMC: 4551295. View

3.
Besharat S, Jabbari A, Semnani S, Keshtkar A, Marjani J . Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol. 2008; 14(23):3725-8. PMC: 2719235. DOI: 10.3748/wjg.14.3725. View

4.
Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

5.
Khushalani N . Cancer of the esophagus and stomach. Mayo Clin Proc. 2008; 83(6):712-22. View